Can you really get off tirzepatide and keep the weight off?
Quick answer
The creator discontinued tirzepatide after significant weight loss and reports continued loss using an unnamed peptide alongside fasting, berberine, food ordering strategies, and hormone management in the context of perimenopause at age 52. SURMOUNT-4 trial data indicates that most patients discontinuing tirzepatide experience substantial weight regain within 52 weeks, making her self-reported outcome a meaningful outlier that warrants scrutiny rather than replication without clinical guidance. The unnamed peptide, referenced with a future purchase link, cannot be clinically evaluated in its current undisclosed form.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @myred.life actually say?
The short version: she lost 35 pounds using tirzepatide, then added an unnamed peptide, and eventually stopped tirzepatide entirely. She says she is now "off at 100%" and has continued losing weight. She credits the unnamed peptide, fasting, light morning exercise, blood sugar management through berberine and apple cider vinegar, and hormone balance. She promises to share the peptide name and a purchase link in a future video.
She is not presenting this as a clinical recommendation. She frames it as her personal experience with practitioner support. That context matters. But 50,000 viewers are not hearing "this worked for me." They are hearing "this is how you get off tirzepatide." That framing carries real downstream risk when the actual mechanism remains a secret punchline held for a future paid link.
Does the science back this up?
Partially, but the headline claim, that an unnamed peptide can replace a GLP-1 agonist and maintain weight loss, has no published evidence supporting it. What the research does support is the surrounding lifestyle strategy she describes.
The problem with stopping tirzepatide is well-documented. Jastreboff et al. (2022, New England Journal of Medicine) showed that participants who stopped tirzepatide in the SURMOUNT-4 trial regained an average of about two-thirds of lost weight within a year. That is the clinical reality this video is implicitly arguing against. Her n-of-1 outcome at roughly one year post-discontinuation is interesting, but it does not overturn a randomized trial.
The lifestyle components she recommends have real support. Berberine has demonstrated modest blood glucose lowering effects in several meta-analyses, including Liang et al. (2019, Evidence-Based Complementary and Alternative Medicine). Time-restricted eating and postprandial glucose management through food ordering are supported by Shukla et al. (2017, Diabetes Care). These are legitimate tools. They are just not proven replacements for a GLP-1 agonist in patients who needed one to lose significant weight.
What did they get wrong, or right?
She got some things right. Hormone balance in perimenopause matters for weight regulation. Estrogen decline drives visceral fat accumulation, and that is backed by Lovejoy et al. (2008, Obesity). Fasting and light exercise as insulin sensitivity tools are legitimate. Eating vegetables first to blunt glucose spikes is a real and underrated strategy.
What she got wrong, or at minimum dangerously incomplete, is the implication that her unnamed peptide is a transferable solution. Without naming it, there is no way to evaluate safety, drug interactions, or whether it is even legal to obtain. "It cost me a couple hundred dollars a month" and a coming purchase link strongly suggests this is a compounded or gray-market peptide product. Viewers with diabetes, thyroid conditions, or cardiovascular history should not be purchasing unidentified injectable or oral peptides based on a TikTok teaser.
She also does not mention that her result may reflect durable metabolic changes from the tirzepatide period itself, not the peptide. GLP-1 agonists can reset appetite signaling, and some patients do maintain well post-discontinuation without any substitute compound.
What should you actually know?
Stopping a GLP-1 agonist like tirzepatide is a legitimate goal for many patients, but the clinical evidence says most people regain weight without a structured maintenance plan. The lifestyle strategies she describes, fasting, food ordering, exercise, and metabolic monitoring, are backed by real research and should be part of any transition plan.
The unnamed peptide is the piece that cannot be evaluated or endorsed. Until she names it, there is no way to assess its evidence base, interaction profile, or regulatory status. Compounded peptides sold online exist in a largely unregulated market. Some are benign. Some are not. A purchase link arriving on TikTok is not a clinical recommendation.
If you are on tirzepatide and wondering about discontinuation, the right conversation is with a prescribing clinician who knows your metabolic history, not a future TikTok video. The lifestyle scaffolding she describes is worth discussing. The mystery compound is not worth purchasing until it has a name, a mechanism, and ideally a peer-reviewed study behind it.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Can you really get off tirzepatide and keep the weight off?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator discontinued tirzepatide after significant weight loss and reports continued loss using an unnamed peptide alongside fasting, berberine, food ordering strategies, and hormone management in the context of perimenopause at age 52.
FormBlends verdict
The creator discontinued tirzepatide after significant weight loss and reports continued loss using an unnamed peptide alongside fasting, berberine, food ordering strategies, and hormone management in the context of perimenopause at age 52. SURMOUNT-4 trial data indicates that most patients discontinuing tirzepatide experience substantial weight regain within 52 weeks, making her self-reported outcome a meaningful outlier that warrants scrutiny rather than replication without clinical guidance. The unnamed peptide, referenced with a future purchase link, cannot be clinically evaluated in its current undisclosed form.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator discontinued tirzepatide after significant weight loss and reports continued loss using an unnamed peptide alongside fasting, berberine, food ordering strategies, and hormone management in the context of perimenopause at age 52. SURMOUNT-4 trial data indicates that most patients discontinuing tirzepatide experience substantial weight regain within 52 weeks, making her self-reported outcome a meaningful outlier that warrants scrutiny rather than replication without clinical guidance. The unnamed peptide, referenced with a future purchase link, cannot be clinically evaluated in its current undisclosed form.
- SURMOUNT-4 trial data (Jastreboff et al., 2022, NEJM) shows roughly two-thirds of lost weight is regained within one year of stopping tirzepatide, making continued loss post-discontinuation an outlier outcome, not the norm.
- The unnamed peptide cannot be fact-checked, safety-evaluated, or clinically endorsed until it is identified. A purchase link without a compound name is not a treatment recommendation.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-4 trial data (Jastreboff et al., 2022, NEJM) shows roughly two-thirds of lost weight is regained within one year of stopping tirzepatide, making continued loss post-discontinuation an outlier outcome, not the norm.
- The unnamed peptide cannot be fact-checked, safety-evaluated, or clinically endorsed until it is identified. A purchase link without a compound name is not a treatment recommendation.
- Berberine has genuine blood glucose lowering data behind it, but its effects are modest and it is not a substitute for prescribed diabetes or metabolic medications.
- Postprandial glucose management through vegetable-first eating is a legitimate, evidence-backed strategy with real trial support from Shukla et al. (2017, Diabetes Care).
- Perimenopause-related hormone changes meaningfully affect weight and fat distribution. Lovejoy et al. (2008, Obesity) confirms this is biology, not willpower.
- Some patients do maintain weight loss after GLP-1 discontinuation without additional compounds, possibly due to appetite signaling changes during the medication period itself.
- Anyone considering stopping tirzepatide should do so with prescriber guidance, not based on a social media protocol built around an unnamed, unverified compound.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
My RED Life · TikTok creator
50.2K views on this video
This is how I have gotten off Tirzepitide and continue to lose weight. I was so scared that I would have to be on it forever. But I found that I absolutely love my new body and feeling like I don’t have to get those shots anymore. #compoundedtirzepatide #tirzepitideweightloss #tirzepatidejourney #menopause #midlifeweightloss #midlifeinfluencer #bodytransformation #womenover50 #postmenopauseweight #postmenopausejourney #postmenopauseproblems #postmenopausefitness
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by My RED Life, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.